ArticleBlood2008
Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers.
Article in Blood, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy.Cancer immunology research · 2026Article
- Distinct host preconditioning regimens differentially impact the antitumor potency of adoptively transferred Th17 cells.Journal for immunotherapy of cancer · 2024Article
- The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook.Frontiers in immunology · 2022Review
- 60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy.Cancer research · 2021Review
- Review
- STING agonist promotes CAR T cell trafficking and persistence in breast cancer.The Journal of experimental medicine · 2021Article
- Human cancer germline antigen-specific cytotoxic T cell-what can we learn from patient.Cellular & molecular immunology · 2020Review
- One-Step Method for Instant Generation of Advanced Allogeneic NK Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2018Article
- DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models.Nature communications · 2018Article
- Safety and Efficacy of Transplantation with Allogeneic Skin Tumors to Treat Chemically-Induced Skin Tumors in Mice.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
- Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity.Oncogene · 2015Article
- Rapid generation of NY-ESO-1-specific CD4Oncoimmunology · 2015Article
- Identification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencing.PloS one · 2014Article
- The DC-HIL ligand syndecan-4 is a negative regulator of T-cell allo-reactivity responsible for graft-versus-host disease.Immunology · 2013Article
- Adoptive immunotherapy for cancer: harnessing the T cell response.Nature reviews. Immunology · 2012Review
- Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma.International reviews of immunology · 2012Review
- Adoptive cell therapy of prostate cancer using female mice-derived T cells that react with prostate antigens.Cancer immunology, immunotherapy : CII · 2011Article
- Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy.Archivum immunologiae et therapiae experimentalis · 2010Review
- CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting.Cancer immunology, immunotherapy : CII · 2010Article
- Adoptive immunotherapy of cancer using CD4(+) T cells.Current opinion in immunology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
Graft-versus-tumor effects can be achieved after allogeneic bone marrow transplantation in patients with malignancies of the kidney or hematopoietic system but are often accompanied by severe graft-versus-host-disease (GVHD). We sought to maximize graft-versus-tumor while minimizing GVHD using tumor-specific allogeneic effector T cells rather than open-repertoire T cells. We transferred allogeneic CD8(+) pmel-1 or CD4(+) TRP-1 T cells specific for the melanoma-associated antigens, glycoprotein 100 (gp100) and tyrosinase-related protein-1 (TRP-1), respectively, into B16-melanoma-bearing mice. Mice receiving a preparative regimen of nonmyeloablating (5 Gy) total body irradiation experienced the rapid rejection of tumor-specific allogeneic lymphocytes with no impact on tumor growth. However, when mice were given more intense total body irradiation conditioning regimens combined with autologous bone marrow transplantation, adoptively transferred allogeneic tumor-specific T lymphocytes persisted at detectable levels for several weeks and mediated significant regression of large, vascularized tumors. We found that the risk of GVHD was low when tumor-specific T cells were transferred and significant toxicity was observed only when substantial numbers of open repertoire allogeneic naive T cells were mixed with the tumor-specific lymphocytes. Taken together, these data indicate that the use of tumor-specific allogeneic CD8(+) T cells or CD4(+) can result in significant antitumor effects in the absence of measurable GVHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.